What Is the GLP-1 Vision Loss Lawsuit About?

The GLP-1 vision loss lawsuit claims that drugs like Ozempic and Wegovy caused NAION, a sudden and usually permanent form of vision loss. It also claims the drug manufacturers failed to warn patients. These claims now have their own federal multidistrict litigation, with more than 200 vision loss lawsuits filed and new cases arriving every month.

This litigation is still early, so your medical records are recent, and your state filing deadline is likely still open. Our attorneys at Uptown Injury Law, PLLC, trace your prescription history, match your diagnosis against the court’s criteria, and file before that deadline runs out. Call 917-540-8728 now for a free case review.

What Are Victims Alleging in the GLP-1 Vision Loss Lawsuit?

Victims in the GLP-1 vision loss lawsuit allege that Novo Nordisk and Eli Lilly knew their drugs could trigger sudden vision loss and failed to warn the users. They point to safety signals in clinical trials and injury reports that reached the drug manufacturers. At the same time, the companies kept marketing these medications for diabetes, weight loss, and weight management.

Plaintiffs seek compensation for the alleged injuries and honest warnings on the drug labels. So far, these are allegations, not proven facts, and the court will decide whether the drugs cause blindness.

Meanwhile, these vision cases are separate from the Ozempic stomach paralysis lawsuit, which covers severe gastrointestinal injuries such as gastroparesis. The same judge oversees both, but each runs as its own case.

Below is the quick overview of the current litigation of the Ozempic vision loss lawsuit:

What Is NAION, the Injury Behind the Lawsuit?

NAION, short for nonarteritic anterior ischemic optic neuropathy, is the injury at the center of this lawsuit. Doctors describe it as an eye stroke. Blood flow to the optic nerve stops, the nerve loses oxygen, and the vision it carries goes dark. NAION typically causes sudden, painless vision loss in one eye, and the loss is usually permanent because optic nerve damage does not heal. No proven treatment exists, and NAION is the second-leading cause of optic nerve blindness.

Victims in these lawsuits describe the same pattern: they woke up with dark patches, blurred vision, or a shadow across part of one eye, often within months of starting the drug. Our attorneys look for that same pattern when we screen a claim. So if you notice sudden vision changes while taking a GLP-1 medication, see an eye doctor immediately and record the date it started. The exam protects your health, and the paper trail it creates anchors your claim to exact dates.

How Is NAION Different From Arteritic AION?

NAION differs from arteritic anterior ischemic optic neuropathy in its cause, and only the non-arteritic type is named in these lawsuits.

• Arteritic AION: caused by artery inflammation, usually strikes older patients, and often brings eye pain. Not part of this litigation.
• NAION (non-arteritic): caused by reduced blood flow and arrives without pain. It appears most often in diabetic patients and in people with sleep apnea, high blood pressure, or a naturally crowded optic nerve.

Those risk factors matter because the manufacturers will point at them and argue that something else caused your vision loss.

So your records decide how strong your claim is. Your diagnosis needs to name the non-arteritic type, and an ophthalmologist’s exam settles that. From there, our attorneys use your full medical history to protect your claim from that defense.

Which GLP-1 Medications Are Named in the Lawsuit?

Seven GLP-1 medications are named in the vision loss lawsuits so far, and both Novo Nordisk and Eli Lilly are facing lawsuits over them. Check your prescription against the list:

Most claims involve semaglutide because researchers tie it to the highest risk of developing NAION. But the details of your prescription do not decide your eligibility. Taking Ozempic for weight loss instead of diabetes still counts, and switching between drugs does not weaken your claim.

Is There Scientific Evidence Linking These Drugs to NAION?

Yes, scientific evidence links GLP-1 drugs to NAION, and how strong that link is will be the central dispute of the lawsuit. The first alarm came from Harvard Medical School, and later research refined the numbers:

• Harvard, 2024: a study in JAMA Ophthalmology found that patients prescribed semaglutide had more than a fourfold higher risk of developing NAION.
• Weight management patients: faced more than a sevenfold higher risk in the same study, the highest risk group identified so far.
• Later reviews: several large studies of patient data found a roughly twofold increased risk among adults with diabetes, and the medical literature keeps growing.

Still, observational studies cannot prove causation on their own, so medical experts will argue this in court. In fact, the absolute risk among GLP-1 users is very low: up to 1 in 10,000 may develop NAION from these drugs.

But rare does not mean minor. For the few victims who suffered, the loss is permanent, and a rare injury still supports a full claim, because each case is judged on its own records.

How Have Regulators and the Manufacturers Responded?

Regulators and the manufacturers have responded in opposite directions. Health agencies abroad now warn patients about NAION, while the drug makers deny the link.

• Europe: in June 2025, the European Medicines Agency concluded that NAION is a very rare side effect of semaglutide, ordered the product information updated across Europe, and said treatment should stop if NAION is confirmed.
• Other countries: more health authorities added similar label updates through 2026.
• United States: The FDA has not required a NAION warning on US drug labels, including Ozempic’s, and its review continues.

So European patients see the risk on their labels, and American patients do not. That gap is the core of the failure-to-warn claims.

The drug makers carry that denial into court, too. When you file, they will argue that the science does not prove your drug caused your vision loss. Our attorneys plan for that from day one, pairing your medical records with expert testimony that connects the drug to your NAION. You do not need to win the science debate. You only need to find out whether you qualify.

Who Qualifies to File a GLP-1 Vision Loss Claim?

You may qualify to file a GLP-1 vision loss claim if you meet three requirements:

• First, you took a GLP-1 medication named in the litigation, whether for diabetes, weight loss, or weight management.
• Second, you suffered sudden vision loss or received a NAION diagnosis.
• Third, your medical records connect the two, with the prescription coming first and the vision loss following it.

Prescription records prove the first, ophthalmology records prove the second, and the timeline between them ties the claim together. You can also seek a review while still taking the medication, since whether to continue is a decision for you and your doctor. The requirements below cover who can file a vision claim specifically; the general rules on who can qualify for an Ozempic, Wegovy, and Mounjaro lawsuit apply as well.

Do You Need a NAION Diagnosis to File a Claim?

No, you do not need a NAION diagnosis in hand to start. A confirmed diagnosis makes the strongest case, but many patients experienced sudden vision loss and never heard the word NAION from their doctor. An ophthalmologist can review your records and establish the diagnosis afterward.

Even records that only describe your symptoms, an ER visit, an urgent care note, or an eye exam that found unexplained loss, give that review something to work with. So if you suffered sudden vision loss after taking a GLP-1 drug, that alone is reason enough for a case review.

Does Partial Vision Loss Qualify?

Yes, partial vision loss qualifies. NAION rarely means total blindness. Instead, it usually brings the sudden loss of part of the sight in one eye. That can mean the lower half of a visual field, the center of your reading vision, or enough lost sharpness that you can no longer drive.

Sudden, permanent impairment is the alleged injury in this litigation, and no rule requires you to have lost everything. The extent of your loss shapes what your claim is worth, not your right to file it.

What if You Had Diabetes or Eye Problems Before?

Pre-existing conditions do not automatically exclude you. After all, diabetes is the reason many patients took a GLP-1 drug in the first place, so the litigation is full of claimants who had it. Prior vision issues or diabetes make causation more fact-specific.

The defense will point to your medical history. However, our lawyers can defend you with a solid eye exam before the drug and sudden vision loss after it is the contrast your claim is built on, backed by the studies above.

What Evidence Supports a Vision Loss Claim?

Ophthalmology records, pharmacy records, your personal timeline, and internal manufacturer documents support a vision loss claim. You already hold most of them:

1. Ophthalmology records: The diagnosis, visual field tests, and optic nerve imaging that map what you lost. Your eye clinic must release them on request. The defense will read these files hunting for gaps, so our attorneys review them first and flag anything missing before it can be used against you.
2. Pharmacy records: Proof of which GLP-1 drug you took, at what dose, and for how long. Also, your pharmacy can print your full dispensing history in one visit. If you switched drugs or pharmacies over the years, our attorneys piece together the complete history for you.
3. Your timeline: The date you started the drug and the date your vision changed, written down while you remember it. This is the one piece of evidence only you can create, and our attorneys turn those two dates into the causation timeline your medical experts build on.
4. Manufacturer documents: What the companies knew and when. These never leave the companies’ files unless lawyers in the litigation force them out through the discovery process, which is where attorneys prove vision loss claims.

Additionally, reporting your injury to FDA MedWatch creates an official record of your vision loss that exists outside any lawsuit. It takes minutes, and it does not affect your right to file.

But you do not need to collect any of this before you call us. From one free case review, our attorneys gather the records, pull the manufacturer documents through discovery, and build the causation argument that turns your paperwork into a claim.

What Are the Latest Updates on the GLP-1 Vision Loss Lawsuit?

The latest updates on the GLP-1 vision loss lawsuit are rapid case growth and the first expert challenges now on the court calendar. Here is what has changed through September 2026:

• The MDL has more than doubled since spring. Cases grew from 86 in May 2026 to 216 by September, and new claims arrive every month. Filing today still places you early in the litigation.
• Filing is faster than it used to be. New cases can be filed directly into MDL 3163, skipping the transfer step that slowed early claims.
• Both sides are building their cases now. The court-appointed plaintiffs’ leadership, the discovery process is underway, and status conferences run on a regular schedule before the judge overseeing both GLP-1 MDLs.
• The first expert challenges are underway. In September 2026, the court heard arguments over the expert witnesses in the sibling stomach-injury MDL. Next, a science day and the bellwether process will follow on the vision side, and those rulings will shape every claim.

Important Note: There is no settlement fund and no sign-up deadline in this litigation. The only real time limit is your state’s filing deadline, the statute of limitations, which generally gives you one to three years from your injury. Our attorneys follow the docket and can tell you exactly how much time you have and what each new ruling means for your claim.

What Compensation Could a Vision Loss Claim Recover?

A successful claim could recover compensation for permanent vision loss, covering both your financial losses and the damage to your daily life:

• Medical expenses: the eye exams, imaging, and specialist visits behind your diagnosis, plus the future care, low-vision aids, and home adjustments permanent vision loss demands.
• Lost wages and earning capacity: the paychecks you missed during diagnosis and treatment, and the long-term income you lose if your career cannot survive impaired vision, especially work that depends on driving or reading.
• Permanent disability: compensation for the impairment itself, counted separately because NAION does not heal.
• Pain and suffering: the mental anguish of losing sight you will not get back, and the independence and activities that went with it.

Although, most mass tort claims resolve through settlement. Even so, our attorneys prepare every claim for trial.

Reported Ozempic lawsuit settlement amounts come from the older stomach-injury cases, not from vision claims. Your claim’s value will depend on the extent of your loss and how it changed your work and daily life.

Contact Our Ozempic Lawsuit Attorneys for a Free NAOIN Case Review

You were simply taking a medication your doctor prescribed for diabetes or weight loss, and it took part of your sight. Now you are wondering who to hold accountable. When a company knows of a risk and sells the drug without a warning, the law calls that negligence, and that is exactly what these lawsuits allege.

You should not have to absorb the losses from someone else’s negligence. At Uptown Injury Law, PLLC,our Ozempic lawsuit lawyerspursue full compensation for you: we build your claim, connect it to the medical evidence, and file before your deadline runs out. For 15+ years, we have held negligent companies accountable for the harm their products cause.

We represent vision loss victims nationwide. You can reach us 24/7, wherever you are, or visit our office at 2417 Third Ave, Suite 505, Bronx, NY 10451. We work on contingency fee basis, so you pay us nothing unless we win your case. Call us 917-540-8728 to get a free case review today!

FAQs